Key points are not available for this paper at this time.
The authors review the nature of the proposal by the FDA for the regulation of next-generation sequencing and laboratory-developed tests in clinical medicine and offer thoughts on what is needed to protect consumers and foster innovation.
Evans et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: